Severe Asthma Overview
Asthma is the most common chronic respiratory disease all over the globe. It affects the airways in the lungs, which become inflamed and narrowed due to various triggers, making it harder for air to flow out. It is a complex activity between airway inflammation and airway remodeling that results in airway hyper-responsiveness (AHR), which further leads to variable and excessive airway contraction.
“Severe Asthma Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Severe Asthma Market.
The Severe Asthma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Severe Asthma Pipeline Report:
- Companies across the globe are diligently working toward developing novel Severe Asthma treatment therapies with a considerable amount of success over the years. Severe Asthma Key players such as – GSK, AstraZeneca, Avillion, 4D Pharma, Novartis, Avalo Therapeutics, Biosion, and others, are developing therapies for the Severe Asthma treatment
- Severe Asthma Emerging therapies such as – GSK3511294 (depemokimab), PT027, PT010, MRx4DP0004, CSJ117 (Ecleralimab), AVTX-002, BSI-045B, and others are expected to have a significant impact on the Severe Asthma market in the coming years.
- In August 2021, the U.S. Food and Drug Administration (FDA) approved tezepelumab (brand name: Tepezza) for the treatment of patients with severe, uncontrolled asthma.
- The TERRANOVA study, which was published in The Lancet Respiratory Medicine in February 2021, demonstrated that treatment with the biologic medication dupilumab significantly reduced severe asthma exacerbations in patients with uncontrolled asthma and high levels of type 2 inflammation.
Route of Administration
Severe Asthma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Molecule Type
Products have been categorized under various Molecule types, such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Severe Asthma Pipeline Therapeutics Assessment
- Severe Asthma Assessment by Product Type
- Severe Asthma By Stage and Product Type
- Severe Asthma Assessment by Route of Administration
- Severe Asthma By Stage and Route of Administration
- Severe Asthma Assessment by Molecule Type
- Severe Asthma by Stage and Molecule Type
DelveInsight’s Severe Asthma Report covers around products under different phases of clinical development like-
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Some of the key companies in the Severe Asthma Therapeutics Market include:
Key companies developing therapies for Severe Asthma treatment are – Adamis Pharmaceuticals Corporation, Aerocrine (Circassia), ALK-Abello A/S, Amphastar Pharmaceuticals, Inc., AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, Cipla, Dimerix, GlaxoSmithKline, Innoviva, Lallemand Pharma International, Merck, Mereo BioPharma Group plc, MundiPharma, Novartis, Pulmatrix, Respiratorius AB, Roche, and others
Emerging Severe Asthma Drugs Under Different Phases of Clinical Development Include:
- GSK3511294 (depemokimab): GSK
- PT027: AstraZeneca/Avillion
- PT010: AstraZeneca
- MRx4DP0004: 4D Pharma
- CSJ117 (Ecleralimab): Novartis
- AVTX-002: Avalo Therapeutics
- BSI-045B: Biosion
Get a Free Sample PDF Report to know more about Severe Asthma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight
Severe Asthma Pipeline Analysis:
The Severe Asthma pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Severe Asthma with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Severe Asthma Treatment.
- Severe Asthma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Severe Asthma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Severe Asthma market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Severe Asthma product details are provided in the report. Download the Severe Asthma pipeline report to learn more about the emerging Severe Asthma therapies
Severe Asthma Pipeline Market Drivers
- Robust Severe Asthma pipeline
- Improving diagnostic approach
- Increasing demand for personalized therapies
- Increasing Prevalent cases of Severe Asthma
Severe Asthma Pipeline Market Barriers
- High cost of Severe Asthma treatment
- Limitations in Severe Asthma diagnosis
- Incorrect inhaler techniques
- Poor Adherence to treatment
Scope of Severe Asthma Pipeline Drug Insight
- Coverage: Global
- Key Severe Asthma Companies: GSK, AstraZeneca, Avillion, 4D Pharma, Novartis, Avalo Therapeutics, Biosion, and others
- Key Severe Asthma Therapies: GSK3511294 (depemokimab), PT027, PT010, MRx4DP0004, CSJ117 (Ecleralimab), AVTX-002, BSI-045B, and others
- Severe Asthma Therapeutic Assessment: Severe Asthma current marketed and Severe Asthma emerging therapies
- Severe Asthma Market Dynamics: Severe Asthma market drivers and Severe Asthma market barriers
Request for Sample PDF Report for Severe Asthma Pipeline Assessment and clinical trials
Table of Contents
1 |
Severe Asthma Report Introduction |
2 |
Severe Asthma Executive Summary |
3 |
Severe Asthma Overview |
4 |
Severe Asthma- Analytical Perspective In-depth Commercial Assessment |
5 |
Severe Asthma Pipeline Therapeutics |
6 |
Severe Asthma Late Stage Products (Phase II/III) |
7 |
Severe Asthma Mid Stage Products (Phase II) |
8 |
Severe Asthma Early Stage Products (Phase I) |
9 |
Severe Asthma Preclinical Stage Products |
10 |
Severe Asthma Therapeutics Assessment |
11 |
Severe Asthma Inactive Products |
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
13 |
Severe Asthma Key Companies |
14 |
Severe Asthma Key Products |
15 |
Severe Asthma Unmet Needs |
16 |
Severe Asthma Market Drivers and Barriers |
17 |
Severe Asthma Future Perspectives and Conclusion |
18 |
Severe Asthma Analyst Views |
19 |
Appendix |
20 |
About DelveInsight |
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report to know more about Severe Asthma drugs and therapies
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432, Las Vegas NV
City: Las Vegas
State: United States
Country: United States
Website: https://www.delveinsight.com